Articles tagged with: Treanda
News»

How has your week been, myeloma world?
Summer definitely is here at Myeloma Morning Headquarters. We had temperatures yesterday and today that rival those normally seen in early August.
We're not exactly sure how we feel about this development.
As for myeloma-related news, we have a lot of ground to cover.
We have one new myeloma research study that we summarize at length. It's about a difficult subject, namely, the impact of early relapse on the overall survival of multiple myeloma patients. It's a difficult subject because, not surprisingly, early relapse continues …
Deutsch»

Liebe Myelomwelt, Ihnen allen einen schönen Samstag.
Wir haben heute über einige gute Nachrichten zu berichten. Es handelt sich dabei auch um wichtige Nachrichten über Darzalex (Daratumumab).
Anfang der Woche wurden einige neue Studienergebnisse veröffentlicht, denen jedoch nicht viel Aufmerksamkeit geschenkt wurde.
Diese neuen Ergebnisse zeigen, dass die Zugabe von Darzalex zu Velcade (Bortezomib) und Dexamethason das progressionsfreie Überleben bei rezidivierten Myelompatienten wesentlich - einige sagen, sogar drastisch – verlängert. Die neuen Ergebnisse gehen über die Nachrichten, die bereits Ende März bekannt gegeben wurden und über die wir in einer vorherigen Ausgabe …
News»

A happy Saturday to you, myeloma world.
We have some good news to report today. It also is important news related to Darzalex (daratumumab).
Some additional clinical trial results related to Darzalex were made public earlier this week, but they have not received much attention.
The new results show that adding Darzalex to Velcade (bortezomib) and dexamethasone substantially – some might even say dramatically – extends progression-free survival in relapsed multiple myeloma patients.
The new results expand on news announced at the end of March, which we covered in …
News»

A happy Tuesday to you, myeloma world.
We have some interesting research to share with you.
First, we have results of a Phase 2 study investigating Empliciti (elotuzumab) in combination with Velcade (bortezomib) and dexamethasone (Decadron) in relapsed and refractory myeloma patients. The results show that Empliciti plus Velcade and dexamethasone improves progression-free survival compared to Velcade and dexamethasone alone, without adding any significant side effects.
We also report on a study out of Italy that explores using Treanda (bendamustine) in addition to melphalan (Alkeran) as the high-dose chemotherapy …
Opinion»

Before I get started, I want to share good news about my ongoing myeloma therapy.
If you recall, after a recent relapse, my doctors and I had decided to try adding Revlimid (lenalidomide) to my doublet of Velcade (bortezomib) and dexamethasone (Decadron) one last time, hoping it might still work. Although it has only been two months, the combination does seem to be helping; my M-spike has dropped from 0.5 g/dL down to 0.4 g/dL, or 20 percent.
But enough about me!
I recently heard from …
News»

This Monday was the third day of the 2013 American Society of Hematology (ASH) annual meeting, which was held in New Orleans.
More than any other day of the conference, Monday was packed with important myeloma presentations, from 7:00 in the morning until almost 8:00 in the evening.
This ASH update will summarize the oral presentation sessions about treatment-related myeloma studies that were held Monday morning. An ASH update that was published on Wednesday focused on the sessions that were held Monday afternoon and evening.
Monday morning started with three simultaneous …
News»

Results from a recent retrospective analysis conducted in Germany indicate that the combination of Velcade plus Treanda and prednisone is effective for relapsed and refractory multiple myeloma patients with kidney impairment.
Specifically, 67 percent of patients responded to the treatment, and kidney function improved in 86 percent of patients. The study investigators point out that the responses were rapid, with a median time to response of three weeks. With a median progression-free survival of 10 months, some patients experienced a long-term treatment-free interval.
Most of the severe side effects of the combination …